Announcement on Appointment of Senior Management Members
Filed with SSE · · 2 pages · Chinese
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Earlier from Gan & Lee Pharmaceuticals
- Announcement on Positive Opinion from the European Medicines Agency's CHMP on the Marketing Authorization Application for Insulin Lispro Injection (Bysumlog®) and Insulin Aspart Injection (Dazparda®)
- Announcement on Change of Sponsor Representative
- Announcement on Expected Increase in Performance for 2025
- Announcement on Obtaining the Ethiopian Drug Registration Approval for Insulin Glargine Injection and Its Pre-filled Injection Pen
- Announcement on Obtaining of European Commission Marketing Authorization for Insulin Glargine Injection
Later from Gan & Lee Pharmaceuticals
- Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection
- Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
- Announcement on the Company Passing ANVISA GMP Certification
- Announcement on Completion of Administration of the First Subject in Phase I Clinical Trial of GLR2037 Tablets
- Announcement on Obtaining Drug Registration Approval by Wholly-owned Subsidiary
Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals